Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01792583 · ClinicalTrials.gov registry record
The Nuvigil and Provigil Pregnancy Registry
A clinical trial, sponsored by Cephalon.
- Terminated
- Registry status
- 191
- Enrollment target
NCT01792583: Clinical Trial study, sponsored by Cephalon.
NCT01792583 is a clinical trial that was terminated before completion, run by Cephalon. The registered enrollment target is 191 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01792583 was terminated before completion, sponsored by Cephalon.
- TERMINATED
- Registry status
- 191 participants
- Enrollment target
Study Summary
The primary objective of the Nuvigil/Provigil Pregnancy Registry is to characterize the pregnancy and fetal outcomes associated with Nuvigil and Provigil exposure during pregnancy.
Primary Outcome
Major birth defects using Metropolitan Atlanta Congenital Birth Defects Program (MACDP) definitions
Interventions
- DRUG Modafinil/armodafinil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 191 participants |
| Start Date | 2009-06-30 |
| Est. Completion | 2023-11-30 |
Why NCT01792583 stopped before completion
NCT01792583 is an observational study that tracks outcomes without assigning an intervention. The registered 191 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Modafinil/armodafinil is the first listed.
NCT01792583 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01792583 about?
NCT01792583 is a clinical study titled "The Nuvigil and Provigil Pregnancy Registry". The primary objective of the Nuvigil/Provigil Pregnancy Registry is to characterize the pregnancy and fetal outcomes associated with Nuvigil and Provigil exposure during pregnancy.
What is the current status of trial NCT01792583?
This trial is currently terminated. The enrollment target is 191 participants. The study started on 2009-06-30. Estimated completion is 2023-11-30.
What interventions are being tested in trial NCT01792583?
The interventions under investigation include: Modafinil/armodafinil (DRUG).
Who is sponsoring clinical trial NCT01792583?
This trial is sponsored by Cephalon, which has 64 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04621435 · 191 participants · Phase 1
Imaging of Solid Tumors Using FAP-2286
- NCT06810544 · 191 participants · Phase 1
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
- NCT01492972 · 192 participants · Phase 3
Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer
- NCT01973881 · 192 participants
Quantitative MRI for Myelofibrosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI